Danno endoteliale, espresso come variazione di Syndecan-1, in chirurgia del rachide con sanguinamento maggiore: studio pilota prospettico osservazionale

Title

Code

GlicOrtho

Type

Osservazionale

Start Year

2022

Status

In Corso

Principal Investigator

091-9297055

jacopo.frugiuele@ior.it

Frugiuele Jacopo, MD

Director

Anesthesia and intensive post-surgery therapy

Operational unit that carry out the study

complex unit

Anestesia e Terapia intensiva post-operatoria

Director

Frugiuele Jacopo, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio clinico prot. GlicOrtho

Tuesday 19 July 2022, 15:55

PG0002547_2022_prot. GlicOrtho.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Danno endoteliale, espresso come variazione di Syndecan-1, in chirurgia del rachide con sanguinamento maggiore: studio pilota prospettico osservazionale

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Danno endoteliale, espresso come variazione di Syndecan-1, in chirurgia del rachide con sanguinamento maggiore: studio pilota prospettico osservazionale

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in